NASDAQ:HOOK Hookipa Pharma (HOOK) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free HOOK Stock Alerts $0.89 +0.09 (+11.20%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.78▼$0.9550-Day Range$0.64▼$0.8952-Week Range$0.41▼$2.05Volume2.89 million shsAverage Volume740,199 shsMarket Capitalization$88.39 millionP/E RatioN/ADividend YieldN/APrice Target$4.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Hookipa Pharma alerts: Email Address Hookipa Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside422.4% Upside$4.67 Price TargetShort InterestHealthy0.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.79 out of 5 starsMedical Sector375th out of 913 stocksPharmaceutical Preparations Industry169th out of 421 stocks 3.5 Analyst's Opinion Consensus RatingHookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHookipa Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.45% of the float of Hookipa Pharma has been sold short.Short Interest Ratio / Days to CoverHookipa Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hookipa Pharma has recently increased by 0.25%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHookipa Pharma does not currently pay a dividend.Dividend GrowthHookipa Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOOK. Previous Next 2.4 News and Social Media Coverage News SentimentHookipa Pharma has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Hookipa Pharma this week, compared to 1 article on an average week.Search Interest15 people have searched for HOOK on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Hookipa Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hookipa Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.82% of the stock of Hookipa Pharma is held by insiders.Percentage Held by Institutions63.88% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Hookipa Pharma are expected to grow in the coming year, from ($0.51) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hookipa Pharma is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hookipa Pharma is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHookipa Pharma has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Hookipa Pharma Stock (NASDAQ:HOOK)HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Read More HOOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOOK Stock News HeadlinesApril 26, 2024 | markets.businessinsider.comBreaking Down HOOKIPA Pharma: 4 Analysts Share Their ViewsApril 25, 2024 | globenewswire.comHOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabApril 27, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Hookipa Pharma Amidst Promising Pipeline and Strategic AdvancementsApril 24, 2024 | globenewswire.comHOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated CancersApril 17, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)April 16, 2024 | finance.yahoo.comHOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)April 10, 2024 | globenewswire.comHOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to RegistrationApril 27, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 27, 2024 | markets.businessinsider.comOptimistic Buy Rating for Hookipa Pharma Based on Promising HB-200 Trial Results and Strategic Trial DesignMarch 24, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 24, 2024 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) OutlookMarch 23, 2024 | benzinga.comHOOKIPA Pharma Stock (NASDAQ:HOOK), Earnings Estimates, EPS, and RevenueMarch 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Hookipa Pharma on Emerging Oncology and Infectious Disease PipelinesMarch 22, 2024 | msn.comHOOKIPA Pharma GAAP EPS of -$0.22 misses by $0.02, revenue of $7.41M beats by $2.85MMarch 22, 2024 | globenewswire.comHOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 6, 2024 | globenewswire.comHOOKIPA Pharma to Participate in Leerink Partners Global Biopharma ConferenceFebruary 28, 2024 | morningstar.comHOOKIPA Pharma Inc HOOKFebruary 22, 2024 | benzinga.comHOOKIPA Pharma Stock (NASDAQ:HOOK) Dividends: History, Yield and DatesFebruary 2, 2024 | finance.yahoo.comAll You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong BuyFebruary 1, 2024 | markets.businessinsider.comMaintaining Buy Rating on Hookipa Pharma Amid Strategic Repositioning and Pipeline PromiseJanuary 31, 2024 | uk.investing.comHookipa Pharma Inc (HOOK)January 29, 2024 | markets.businessinsider.comStrategic Focus on Promising HPV+ Cancer Candidate Underpins Buy Rating for Hookipa PharmaJanuary 29, 2024 | markets.businessinsider.comHOOKIPA Pharma To Cut Jobs Following Collaboration Termination By RocheJanuary 29, 2024 | msn.comRoche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer DealJanuary 29, 2024 | marketwatch.comHOOKIPA Pharma Shares Fall Premarket as Roche Ends CollaborationJanuary 16, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationSee More Headlines Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today4/27/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HOOK CUSIPN/A CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees56Year FoundedN/APrice Target and Rating Average Stock Price Target$4.67 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+422.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net Margins-405.28% Pretax Margin-403.46% Return on Equity-72.30% Return on Assets-40.51% Debt Debt-to-Equity RatioN/A Current Ratio3.50 Quick Ratio3.50 Sales & Book Value Annual Sales$20.13 million Price / Sales4.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book0.98Miscellaneous Outstanding Shares98,950,000Free Float93,191,000Market Cap$88.39 million OptionableOptionable Beta1.02 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Joern Aldag (Age 60)Pres, CEO & Director Mr. Daniel Pinschewer (Age 44)Founder & Chief Scientific Officer Dr. Reinhard Kandera (Age 50)CFO & Director Mr. Anders Lilja Ph.D. (Age 46)Sr. VP of Technical Devel. Mrs. Nina WaibelCommunications & Investor Relations Mang.Key CompetitorsTempest TherapeuticsNASDAQ:TPSTYS BiopharmaNASDAQ:YSCorvus PharmaceuticalsNASDAQ:CRVSConnect BiopharmaNASDAQ:CNTBSpero TherapeuticsNASDAQ:SPROView All CompetitorsInsidersReinhard KanderaBought 7,000 shares on 8/21/2023Total: $5,040.00 ($0.72/share)Reinhard KanderaBought 8,000 shares on 8/16/2023Total: $5,680.00 ($0.71/share)Jorn AldagBought 5,000 shares on 7/11/2023Total: $4,150.00 ($0.83/share)Jorn AldagBought 5,000 shares on 7/7/2023Total: $4,050.00 ($0.81/share)Jorn AldagBought 5,000 shares on 7/5/2023Total: $4,450.00 ($0.89/share)View All Insider Transactions HOOK Stock Analysis - Frequently Asked Questions Should I buy or sell Hookipa Pharma stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOOK shares. View HOOK analyst ratings or view top-rated stocks. What is Hookipa Pharma's stock price target for 2024? 3 analysts have issued twelve-month price objectives for Hookipa Pharma's shares. Their HOOK share price targets range from $4.00 to $5.00. On average, they anticipate the company's stock price to reach $4.67 in the next year. This suggests a possible upside of 422.4% from the stock's current price. View analysts price targets for HOOK or view top-rated stocks among Wall Street analysts. How have HOOK shares performed in 2024? Hookipa Pharma's stock was trading at $0.81 on January 1st, 2024. Since then, HOOK stock has increased by 10.3% and is now trading at $0.8933. View the best growth stocks for 2024 here. Are investors shorting Hookipa Pharma? Hookipa Pharma saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 315,900 shares, a drop of 5.2% from the March 15th total of 333,400 shares. Based on an average trading volume of 562,100 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.5% of the company's shares are short sold. View Hookipa Pharma's Short Interest. When is Hookipa Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HOOK earnings forecast. How were Hookipa Pharma's earnings last quarter? Hookipa Pharma Inc (NASDAQ:HOOK) posted its quarterly earnings data on Friday, March, 22nd. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.09. The business had revenue of $7.41 million for the quarter, compared to analysts' expectations of $3.60 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 72.30% and a negative net margin of 405.28%. What other stocks do shareholders of Hookipa Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC), Alector (ALEC), Precision BioSciences (DTIL), Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX). When did Hookipa Pharma IPO? Hookipa Pharma (HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager. How do I buy shares of Hookipa Pharma? Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HOOK) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
